Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Bortezomib in Patients With Metastatic Papillary or Follicular Thyroid Cancer Unresponsive to Prior Radioiodine Therapy

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Active	18 and over	NCI	MDA-2004-0059 6132, NCI-6132, NCT00104871

Trial Description

Purpose:

Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable disease
• Cancer did not respond to previous radioactive iodine therapy
• No brain metastases
• No more than 2 previous chemotherapy regimens
• At least 1 month since chemotherapy
• At least 6 months since radioactive iodine therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive an infusion of bortezomib twice a week for 2 weeks. Treatment may repeat every 3 weeks for at least four courses.

Patients will be evaluated periodically.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Steven Sherman, MD, Protocol chair		Ph: 713-792-2841; 800-392-1611 Email: sisherma@mdanderson.org

U.S.A.
Colorado
	Aurora
	University of Colorado Cancer Center at UC Health Sciences Center
		Bryan Haugen, MD	Ph:  303-315-8443
Texas
	Houston
	M. D. Anderson Cancer Center at University of Texas
		Clinical Trials Office - M. D. Anderson Cancer Center at the University of Texas	Ph:  713-792-3245
Canada
Ontario
	Toronto
	Princess Margaret Hospital
		J. D. Brierley, MD	Ph:  416-946-2124
			Email: james.brierly@rmp.uhn.on.ca

Registry Information
Official Title		A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Cancer
Trial Start Date		2004-12-22
Trial Completion Date		2006-03-17 (estimated)
Registered in ClinicalTrials.gov		NCT00104871
Date Submitted to PDQ		2005-01-06
Information Last Verified		2008-12-21
NCI Grant/Contract Number		CM17107, CM17003, CA16672